Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2017–2022

PREDICT · A new era in personalised medicine: Radiomics as decision support tool for diagnostics and theragnostics in oncology

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2017-10-01 → 2022-03-31
EU contribution
€3,588,939
Participants
18
Scheme
MSCA-ITN-ETN

Lines connect the coordinator with its partners.

Results in brief

A new era in personalised medicine: Radiomics as decision support tool for diagnostics and theragnostics in oncology

PREDICT is a MarieCurie innovative training network that aims at training a new generation of early stage researchers to become leaders in the field of Radiomics and personalised medicine, ultimately aimed at improving the diagnosis and treatment of cancer. Tumour cells can differ greatly both between patients (inter-tumour heterogeneity) and within patients (intra-tumour heterogeneity). These differences affect how patients respond to cancer therapy and hampers wide deployment of personalised medicine for cancer treatment. PREDICT is an Innovative Training Network that will educate 14 Early Stage Researcher (ESRs) in the fields of radiomics and personalised medicine. These ESRs will be trained to use big data analytics on large amounts of radiographic images to determine tumour heterogeneity and predict how patients will respond to treatment. Conclusion The PREDICT project successfully trained 14 ESR's to to become professionals and business experts in Radiomics, Big Data, machine learning approaches, and multifactorial DSS. All projects yielded interesting results and contributed to the field of Radiomics and Personalised medicine.

Data: CORDIS, © European Union

Project objective

The high degree of tumour (genomic and phenotypic) heterogeneity influences patient’s response to therapy and hampers wide deployment of personalised medicine for cancer treatment. Thus, there is an imperative need for new technologies that can accurately detect tumour heterogeneity, allow for patient stratification and assist clinicians in providing the right diagnosis and treatment for the right patient. PREDICT’s mission is to address this huge unmet need.Radiomics, a newly emerging field that uses high-throughput extraction of large amounts of features from radiographic images, can boost the field of personalised medicine. The analysis of medical images taken as standard-of-care allows Radiomics to capture tumour heterogeneity and to generate ‘tumour-specific’ signatures in a non-invasive way, without the need of assessing the patient’s genetic profile. Thus, Radiomics, if linked to Big- data and decision support systems (DSS), can be used as diagnostic tool for patient stratification, for prediction of treatment response and for guidance, involving the patient, of clinical decisions in oncology. However, researchers that understand cancer biology, advanced imaging and big data analytics are virtually absent. Even more challenging is to translate the outcomes into actual clinical tools involving the patient.PREDICT will train 15 highly promising researchers in the emerging field of Radiomics and Big data. These ESRs will be trained to implement the automatic exploitation of large amounts of imaging data to drive decision-making algorithms that will guide diagnosis and treatment of different types of cancer and to develop ‘tumour-specific’ signatures integrated in multifactorial DSS. The ESRs will become experts and innovators in Radiomics, Big Data and DSS, which will allow them to bring unique solutions towards the clinic. PREDICT builds upon a strong consortium with 8 academic and 10 non-academic partners that are all pioneers in their respective field.

Original text from CORDIS.

Participants

  • UNIVERSITEIT MAASTRICHT · MaastrichtCoordinatorNetherlands
  • DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG · HeidelbergGermany
  • ELSEVIER BV · AmsterdamNetherlands
  • ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM · RotterdamNetherlands
  • EUROPEAN CANCER PATIENT COALITION · Bruxelles / BrusselBelgium
  • EXOMNIS BIOTECH · MaastrichtNetherlands
  • FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI · MilanItaly
  • HEALTH INNOVATION VENTURES BV · MAASTRICHTNetherlands
  • HEIDELBERGER IONENSTRAHL THERAPIE (HIT) BETRIEBS GESELLSCHAFT AM UNIVERSITATSKLINIKUM HEIDELBERG MIT BESCHRANKTER HAFTUNG · HeidelbergGermany
  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · ParisFrance
  • MIRADA MEDICAL LTD · OxfordUnited Kingdom
  • ONCORADIOMICS · LIEGEBelgium
  • PERSPECTUM LTD · OXFORDUnited Kingdom
  • PNO Life Sciences & Health B.V. · RijswijkNetherlands
  • Siemens · MunichGermany
  • UNIVERSITATSKLINIKUM HEIDELBERG · HeidelbergGermany
  • UNIVERSITE DE LIEGE · LIEGEBelgium
  • Universita' Cattolica S. Cuore, Roma · RomaItaly

Links

Data: CORDIS, © European Union